227 related articles for article (PubMed ID: 19091991)
1. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
Boaz MJ; Hayes P; Tarragona T; Seamons L; Cooper A; Birungi J; Kitandwe P; Semaganda A; Kaleebu P; Stevens G; Anzala O; Farah B; Ogola S; Indangasi J; Mhlanga P; Van Eeden M; Thakar M; Pujari A; Mishra S; Goonetilleke N; Moore S; Mahmoud A; Sathyamoorthy P; Mahalingam J; Narayanan PR; Ramanathan VD; Cox JH; Dally L; Gill DK; Gilmour J
Clin Vaccine Immunol; 2009 Feb; 16(2):147-55. PubMed ID: 19091991
[TBL] [Abstract][Full Text] [Related]
2. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.
Sambor A; Garcia A; Berrong M; Pickeral J; Brown S; Rountree W; Sanchez A; Pollara J; Frahm N; Keinonen S; Kijak GH; Roederer M; Levine G; D'Souza MP; Jaimes M; Koup R; Denny T; Cox J; Ferrari G
J Immunol Methods; 2014 Jul; 409():107-16. PubMed ID: 24787274
[TBL] [Abstract][Full Text] [Related]
3. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
Cox JH; Ferrari G; Kalams SA; Lopaczynski W; Oden N; D'souza MP;
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):68-81. PubMed ID: 15665646
[TBL] [Abstract][Full Text] [Related]
4. The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.
Sarzotti-Kelsoe M; Needham LK; Rountree W; Bainbridge J; Gray CM; Fiscus SA; Ferrari G; Stevens WS; Stager SL; Binz W; Louzao R; Long KO; Mokgotho P; Moodley N; Mackay M; Kerkau M; McMillion T; Kirchherr J; Soderberg KA; Haynes BF; Denny TN
J Immunol Methods; 2014 Jul; 409():21-30. PubMed ID: 24910414
[TBL] [Abstract][Full Text] [Related]
5. Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.
Ducar C; Smith D; Pinzon C; Stirewalt M; Cooper C; McElrath MJ; Hural J;
J Immunol Methods; 2014 Jul; 409():9-20. PubMed ID: 24709391
[TBL] [Abstract][Full Text] [Related]
6. The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.
Sanchez AM; Rountree W; Berrong M; Garcia A; Schuetz A; Cox J; Frahm N; Manak M; Sarzotti-Kelsoe M; D'Souza MP; Denny T; Ferrari G
J Immunol Methods; 2014 Jul; 409():31-43. PubMed ID: 24685833
[TBL] [Abstract][Full Text] [Related]
7. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators.
Zhang W; Caspell R; Karulin AY; Ahmad M; Haicheur N; Abdelsalam A; Johannesen K; Vignard V; Dudzik P; Georgakopoulou K; Mihaylova A; Silina K; Aptsiauri N; Adams V; Lehmann PV; McArdle S
J Immunotoxicol; 2009 Dec; 6(4):227-34. PubMed ID: 19908941
[TBL] [Abstract][Full Text] [Related]
8. Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials.
Langat RK; Farah B; Indangasi J; Ogola S; Omosa-Manyonyi G; Anzala O; Bizimana J; Tekirya E; Ngetsa C; Silwamba M; Muyanja E; Chetty P; Jangano M; Hills N; Gilmour J; Dally L; Cox JH; Hayes P
Afr J Lab Med; 2021; 10(1):1056. PubMed ID: 33833946
[TBL] [Abstract][Full Text] [Related]
9. Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Janetzki S; Price L; Britten CM; van der Burg SH; Caterini J; Currier JR; Ferrari G; Gouttefangeas C; Hayes P; Kaempgen E; Lennerz V; Nihlmark K; Souza V; Hoos A
Cancer Immunol Immunother; 2010 Apr; 59(4):609-18. PubMed ID: 19894047
[TBL] [Abstract][Full Text] [Related]
10. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
Mwau M; McMichael AJ; Hanke T
AIDS Res Hum Retroviruses; 2002 Jun; 18(9):611-8. PubMed ID: 12079556
[TBL] [Abstract][Full Text] [Related]
11. Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
Gill DK; Huang Y; Levine GL; Sambor A; Carter DK; Sato A; Kopycinski J; Hayes P; Hahn B; Birungi J; Tarragona-Fiol T; Wan H; Randles M; Cooper AR; Ssemaganda A; Clark L; Kaleebu P; Self SG; Koup R; Wood B; McElrath MJ; Cox JH; Hural J; Gilmour J
PLoS One; 2010 Dec; 5(12):e14330. PubMed ID: 21179404
[TBL] [Abstract][Full Text] [Related]
12. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
Bull M; Lee D; Stucky J; Chiu YL; Rubin A; Horton H; McElrath MJ
J Immunol Methods; 2007 Apr; 322(1-2):57-69. PubMed ID: 17382342
[TBL] [Abstract][Full Text] [Related]
13. Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop G; Leroux-Roels G; Pagnon A; Begue S; Salaun B; Janssens M; Medaglini D; Pettini E; Montomoli E; Gianchecchi E; Lambe T; Godfrey L; Bull M; Bellamy D; Amdam H; Bredholt G; Cox RJ; Clement F
J Immunol Methods; 2023 Dec; 523():113584. PubMed ID: 37918618
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.
Samri A; Durier C; Urrutia A; Sanchez I; Gahery-Segard H; Imbart S; Sinet M; Tartour E; Aboulker JP; Autran B; Venet A;
Clin Vaccine Immunol; 2006 Jun; 13(6):684-97. PubMed ID: 16760328
[TBL] [Abstract][Full Text] [Related]
15. The role of IFN-gamma Elispot assay in HIV vaccine research.
Streeck H; Frahm N; Walker BD
Nat Protoc; 2009; 4(4):461-9. PubMed ID: 19282851
[TBL] [Abstract][Full Text] [Related]
16. Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
Mander A; Gouttefangeas C; Ottensmeier C; Welters MJ; Low L; van der Burg SH; Britten CM
Cancer Immunol Immunother; 2010 Apr; 59(4):619-27. PubMed ID: 20052465
[TBL] [Abstract][Full Text] [Related]
17. Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot.
Trück J; Mitchell R; Thompson AJ; Morales-Aza B; Clutterbuck EA; Kelly DF; Finn A; Pollard AJ
Hum Vaccin Immunother; 2014; 10(8):2490-6. PubMed ID: 25424961
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Asai T; Storkus WJ; Whiteside TL
Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
[TBL] [Abstract][Full Text] [Related]
19. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.
Filbert H; Attig S; Bidmon N; Renard BY; Janetzki S; Sahin U; Welters MJ; Ottensmeier C; van der Burg SH; Gouttefangeas C; Britten CM
Cancer Immunol Immunother; 2013 Apr; 62(4):615-27. PubMed ID: 23138872
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.
Patton K; Aslam S; Lin J; Yu L; Lambert S; Dawes G; Esser MT; Woo J; Janetzki S; Cherukuri A
Clin Vaccine Immunol; 2014 May; 21(5):628-35. PubMed ID: 24574540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
